America Great Health (AAGH) 10-K 24 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	No
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	America Great Health
Entity Central Index Key	0001098009
Entity File Number	000-27873
Entity Tax Identification Number	98-0178621
Entity Incorporation, State or Country Code	WY
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 0
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1609 W Valley Blvd, Unit 338A
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91803
Entity Phone Fax Numbers [Line Items]
City Area Code	(888)
Local Phone Number	988-1333
Entity Listings [Line Items]
Title of 12(b) Security	None
Entity Common Stock, Shares Outstanding		21,188,988,326

Audit Information

Audit Information	12 Months Ended
	Jun. 30, 2024
Auditor [Table]
Auditor Name	Gries & Associates LLC
Auditor Firm ID	6580
Auditor Location	Los Angeles, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Jun. 30, 2023
CURRENT ASSETS
Cash	$ 54,943	$ 54,150
Account receivable, net	55,100	0
Inventory	83,141	108,351
Prepaid and other assets	32,295	16,964
TOTAL CURRENT ASSETS	225,479	179,465
Right-of-use asset, net	43,260	41,918
Due from the related parties	0	8,218
Other assets	11,836	11,836
Property and equipment, net	42,903	57,692
TOTAL ASSETS	323,478	299,129
CURRENT LIABILITIES
Accounts payable	1,435,854	1,450,574
Income tax payable	1,685	3,970
Short term loan	606,978	727,003
Other payable	357,472	241,784
Due to related party	1,110,196	425,142
Advances from customers	59,600	68,331
Lease liability – current	21,683	41,918
TOTAL CURRENT LIABILITIES	3,593,468	2,958,722
Lease liability – non-current	21,577	0
Accrued liabilities	186,455	186,455
Long term loan	1,833,577	1,524,788
Total Non-Current liabilities	2,041,609	1,711,243
TOTAL LIABILITIES	5,635,077	4,669,965
Commitments and Contingencies	0	0
SHAREHOLDERS’ DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding	0	0
Common stock, no par value, unlimited shares authorized; 21,136,888,326 and 21,107,018,148 shares issued and outstanding	0	0
Additional paid-in capital	5,019,059	4,732,477
Accumulated other comprehensive income	(1,483)	(500)
Accumulated deficit	(10,248,681)	(9,028,110)
Total deficit attributable to owners of the Company	(5,231,105)	(4,296,133)
Non-controlling interest	(80,494)	(74,703)
TOTAL SHAREHOLDERS’ DEFICIT	(5,311,599)	(4,370,836)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 323,478	$ 299,129

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - shares	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Series A voting preferred stock, shares issued	0	0
Series A voting preferred stock, shares outstanding	0	0
Redeemable, convertible preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	21,136,888,326	21,107,018,148
Common stock, shares outstanding	21,136,888,326	21,107,018,148

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Sales	$ 294,670	$ 204,308
Cost of goods sold	124,920	35,720
Gross profit	169,750	168,588
Selling, general and administrative expenses
Selling expense	95,835	3,999
General and administrative expense	856,615	657,233
Selling, general and administrative expenses	952,450	661,232
Loss from operations	(782,700)	(492,644)
Other income (expenses)
Interest income	61	26
Interest expense	(443,723)	(319,705)
Other income	0	34,983
Other income (expenses)	(443,662)	(284,696)
Loss before income taxes	(1,226,362)	(777,340)
NET LOSS	$ (1,226,362)	$ (777,340)
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0	$ 0
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0	$ 0
BASIC AND DILUTED (in Shares)	21,123,253,567	21,093,402,806
BASIC AND DILUTED (in Shares)	21,123,253,567	21,093,402,806
Non-controlling interest share of loss	$ (5,791)	$ (15,920)
Net loss attributed to the owners of the Company	(1,220,571)	(761,420)
Foreign currency transaction	983	660
Comprehensive loss	$ (1,219,588)	$ (760,760)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Accumulated Deficit - USD ($)	Common Stock	Additional paid-in Capital	Accumulated Other Comprehensive Income/(Loss)	Accumulated Deficit During Period	Total Deficit Attributable to the Owners of the Company	Non- Controlling Interest	Treasury Stock	Total
Balance at Jun. 30, 2022		$ 4,619,992	$ 160	$ (8,266,850)	$ (3,646,698)	$ (58,783)		$ (3,705,481)
Balance (in Shares) at Jun. 30, 2022	21,090,218,148
Issuance of common stock for debt		26,200			26,200			26,200
Issuance of common stock for debt (in Shares)	4,600,000
Issuance of common stock for compensation		65,880			65,880			65,880
Issuance of common stock for compensation (in Shares)	12,200,000
Imputed interest		5,205	(660)		4,545			4,545
Gain/loss on exchange rate				160	160			160
Original issue discount on debt		15,200			15,200			15,200
Net loss				(761,420)	(761,420)	(15,920)		(777,340)
Balance at Jun. 30, 2023		4,732,477	(500)	(9,028,110)	(4,296,133)	(74,703)		$ (4,370,836)
Balance (in Shares) at Jun. 30, 2023	21,107,018,148							21,107,018,148
Issuance of common stock for debt (in Shares)	8,000,000
Issuance of common stock for equity investment		115,000			115,000			$ 115,000
Issuance of common stock for equity investment (in Shares)	10,500,000
Issuance of common stock for compensation		123,582			123,582			123,582
Issuance of common stock for compensation (in Shares)	11,370,178
Treasury Shares (in Shares)							52,100,000
Gain/loss on exchange rate			(983)		(983)			(983)
Original issue discount on debt		48,000			48,000			48,000
Net loss				(1,220,571)	(1,220,571)	(5,791)		(1,226,362)
Balance at Jun. 30, 2024		$ 5,019,059	$ (1,483)	$ (10,248,681)	$ (5,231,105)	$ (80,494)		$ (5,311,599)
Balance (in Shares) at Jun. 30, 2024	21,136,888,326						52,100,000	21,136,888,326

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net loss	$ (1,226,362)	$ (777,340)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	14,789	10,346
Original issue discount	48,000	15,200
Stock compensation	123,582	65,880
Imputed interest	0	5,205
Provision for inventory obsolescence, net	9,400	0
Payment of lease and rent	(80,438)	(75,706)
Changes in operating Assets and Liabilities:
Right of use asset – net	(1,342)	51,968
Lease liabilities – net	47,207	23,738
Account receivable – net	(55,100)	919
Prepaid expenses and other assets	(15,331)	0
Other long term asset	0	2,000
Inventory	15,810	7,709
Accounts payable and accrued expense	19,853	13,050
Customer advances	(8,731)	66,331
Accrued interest for short term loan	117,845	59,356
Accrued interest for long term loan	261,789	237,857
Other liabilities	0	(7,863)
Income Tax	800	800
Other payable	112,602	(89,259)
Net cash used in operating activities from continuing operations	(615,627)	(389,809)
Net cash used in operating activities	(615,627)	(389,809)
Cash Flows from Investing Activities
Purchase of property and equipment	0	(44,420)
Net cash used in investing activities	0	(44,420)
Cash Flows from Financing Activities
Proceeds from issuance of common stock	115,000	26,200
Proceeds of short term loan	37,475	565,216
Repayment of short term loan	(201,941)	(43,932)
Interest payment to short term loan	(73,403)	(59,356)
Proceeds of long term loan	60,000	91,000
Repayment of long term loan	(10,000)	0
Interest payment to long term loan	(3,000)	(4,175)
Advances from related party	969,868	224,422
Repayment to related party	(276,596)	(373,140)
Net cash provided by financing activities	617,403	426,235
Net increase in cash	1,776	(7,994)
Cash beginning of period	54,150	62,643
Effect of foreign currency translation	(983)	(499)
Cash end of period	54,943	54,150
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION
Interest paid	76,403	63,531
Taxes paid	800	800
Non-cash investing and financing information:
Shares issued for equity investment	$ 0	$ 0

NATURE OF BUSINESS

NATURE OF BUSINESS	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
NATURE OF BUSINESS	NOTE 1 NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021. On December 7, 2020, the Company’s wholly-owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China as “Sijinsai (Hainan) Biological Tech Ltd.” On July 9, 2021, the Company paid its first investment of $50,000. In July 2021, the Company paid Dr. Aihua Guo $100,000 as prepaid investment. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready for production. On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement. The 500,000 shares were issued free in April 20, 2022. On November 15, 2021, the Company set up a 100% owned subsidiary GOF Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin would be appointed Chief Executive Officer of GOF. The employment agreement and supplement agreement were both terminated by the end of July 2022 without the issuance of any GOF shares. On February 4, 2021, the Company set up a 100% owned subsidiary, International Institute of Great Healthcare, Inc. (“IIGH”) under the laws of the State of California. IIGH will bring together doctors and professional-level experts from different countries and regions in the world to the research fields involving biomedicine, clinic medicine, health management, information technology, data analysis, software development, artificial intelligence, industrial planning, financial investment, etc. On November 25, 2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party. The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai’s successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price. On November 26, 2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party and transferred pending anti-dementia patent to Men Hwei, Tsai for $34,978.48. Going Concern The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2024, the Company recorded a net loss of $1,226,362, used cash to fund operating activities of $615,627, and on June 30, 2024, had a shareholders’ deficit of $5,311,599. These factors create substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. The Company’s cash needs for the 12 months ended June 30, 2024 were primarily met by loans and advances from the current majority shareholder. As of June 30, 2024, the Company had a cash balance of $54,943. The Company intends to finance operating costs over the next twelve months with existing cash on hand and advance from the current majority shareholder.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company has adjusted certain previously reported amounts in its balance sheets as of and for the year ended June 30, 2023 to reflect the recording of the advances from customers, netting the corresponding accumulated deficit for an amount of $155,000 which was originally recognized as revenue. This adjustment did not materially impact the financial position and the result of operations of the Company for the year indicated. Basis of Consolidation The Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), US-China Mega Beauty Health Industry Development Co., LTD, (100%), and Peptide Life Inc in California (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Peptide Life Inc in California USA 100 Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ deficit. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of Meizhong Health Industry Development Co., Ltd. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) 2024 Chinese Renminbi (RMB) RMB 7.2139 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) 2024 Chinese Renminbi (RMB) RMB 7.2674 United States dollar ($) $ 1.00 Reclassification of Prior Year Presentations Certain prior year accounts and amounts have been reclassified for consistency with the current year presentation. These reclassifications have no effect on the reported results of operations. Below is the comparison of the reclassification and the original representation of the related accounts and amounts. Consolidated Balance Sheet Reclassified Original June 30, June 30, 2023 Short term loan $ 727,003 $ 705,216 Accrued liabilities 186,455 609,892 Deferred income - 223,331 Advances from customers 68,331 - Long term loan 1,524,788 1,123,138 Accumulated deficit (9,028,110 ) (9,183,110 ) Total $ (6,521,533 ) (6,521,533 ) Consolidated Statement of Cash Flows Reclassified Original June 30, 2023 June 30, 2023 Proceed from issuance of common stocks $ 26,200 $ 92,080 Payment of leases and rent (75,706 ) - Right of use asset – net 51,968 - Lease liabilities – net 23,738 - Stock based comprehension 65,880 - Short term loan - 521,284 Short term loan – proceeds 565,216 - Short term loan – repayment (43,932 ) - Accrued interest for short term loan 59,356 - Short term loan – interest paid (59,356 ) - Income tax payable 800 - Other payable (89,259 ) (88,459 ) Long term loan - 324,682 Long term loan – proceeds 91,000 - Accrued interest for long term loan 237,857 - Long term loan – interest paid (4,175 ) - Advances from related parties 224,422 (148,718 ) Repayment to related parties (373,140 ) - Total $ 700,869 $ 700,869 Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2024 and 2023, the Company’s bank account in the United States had $9,355 and $4,131, respectively, under FDIC insurance of $250,000. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health-related products through wholesale and retailers. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company usually does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date and 180 days for a major customer, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted on the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time when shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. Any payment received prior to shipment is recognized as a contract liability under the account deferred revenue. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed by third-party carriers for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in the cost of sales for all periods presented. Account Receivable The Company has been developing its new products and launching large-scale production since November 2023. As of June 30, 2024 net accounts receivable amounted to $55,100. The Company has not established a reserve for uncollectible amounts on the newly launched products since the historical data on bad debts in the aging categories of the new products could not support such estimates. For the year ended June 30, 2024, the Company has $23,400 of allowance for bad debt. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the year ended June 30, 2024, the Company has $9,400 of inventory valuation reserve. At the end of fiscal years 2024 and 2023, inventories comprised: June 30, June 30, Raw materials $ 56,435 $ 62,348 Finished goods 36,106 46,003 Inventory valuation reserve (9,400 ) - Subtotal $ 83,141 $ 108,351 Cost of Goods Sold The cost of goods sold includes product costs only and is recorded in the same period in which related revenues have been recorded. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Machinery and equipment 5 years At the end of fiscal years 2024 and 2023, machinery and equipment at cost and accumulated depreciation were: June 30, June 30, Machinery and equipment $ 73,943 $ 73,943 Accumulated depreciation (31,040 ) (16,251 ) Subtotal $ 42,903 $ 57,692 Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Stock-based Compensations The Company offers restricted stock-based compensations to the employees and contractors. All stock-based compensations are measured based on their values and are expensed over the period during which an employee or a contractor is required to provide service in exchange for the compensations. Treasury Stock Shares Treasury shares are recognized at acquisition cost and are presented as a deduction from shareholder’s equity. Upon sale of treasury shares, the realized gain or loss is recognized through the income statement as income or expense from financial assets. Loss Per Share Basic earnings (loss) per share are computed by dividing the income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2024 and 2023, as there are no potential shares outstanding that would have a diluted effect. Income Taxes Income tax expenses are based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In July 2023, the FASB issued Accounting Standard Update (“ASU”) No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation (Topic 718). As ASU 2023-03 did not provide any new guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company’s consolidated financial statement presentation or related disclosures. In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), Income Taxes (Topic 740): Improvements to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. As the amendments apply to income tax disclosures only, the Company does not expect adoption to have a material impact on our consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

OTHER ASSET

OTHER ASSET	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
OTHER ASSET	NOTE 3 OTHER ASSET As of June 30, 2024 and 2023, other assets amounted to $11,836 for both years. Other assets consist of the following: June 30, June 30, Rent deposits 11,836 11,836 Total 11,836 11,836

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4 RELATED PARTY TRANSACTIONS During the year ended June 30, 2024, the Company’s current majority shareholder advanced $969,868 to the Company as working capital and the Company repaid $276,596 to the shareholder. As of June 30, 2024 and 2023, the Company owed its current shareholder of $1,110,196 and $425,142 respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted to $- and $5,205 for the years ended June 30, 2024 and 2023 and was recorded as paid in capital, respectively.

SHORT TERM LOAN

SHORT TERM LOAN	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
SHORT TERM LOAN	NOTE 5 SHORT TERM LOAN As of June 30, 2024 and 2023, short term loan principals amounted to $540,750 and $705,216 from unrelated third parties, respectively. As of June 30, 2024, the Company paid off $150,000 to the loan received on January 13, 2023. Short Term Loans As of June 30, 2024 As of June 30, 2023 Receiving Maturity Principal Accrued Total Principal Accrued Total 2024 1/13/2023 1/13/2024 $ -- $ 27,200 $ 27,200 $ 150,000 $ 5,809 $ 155,809 20 % 1/19/2023 1/18/2024 300,000 39,028 339,028 300,000 15,978 315,978 13 % 2/6/2023 7/2/2024 750 - 750 15,216 - 15,216 316 % 2/25/2023 6/24/2023 100,000 - 100,000 100,000 - 100,000 24 % 3/1/2023 8/31/2023 10,000 - 10,000 10,000 - 10,000 20 % 3/1/2023 8/31/2023 50,000 - 50,000 50,000 - 50,000 20 % 3/1/2023 9/30/2023 30,000 - 30,000 30,000 - 30,000 10 % 3/1/2023 9/30/2023 50,000 - 50,000 50,000 - 50,000 10 % Total $ 540,750 $ 66,228 $ 606,978 $ 705,216 $ 21,787 $ 727,003

LONG TERM LOAN

LONG TERM LOAN	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
LONG TERM LOAN	NOTE 6 LONG TERM LOAN As of June 30, 2024 and 2023, long term loan principals amounted to $1,173,138 and $1,123,138, respectively. The loan has an annual interest rate of 20%. The principal and interest are due in five years from the original dates of the loans. Interest expenses of the long-term loans incurred for the years ended June 30, 2024 and 2023 amounted to $222,745 and $212,704, respectively. As of June 30, 2024, the Company paid off $10,000 to the loan received on September 30, 2021 and $3,000 interest as well. Most long-term loans are pledged with the Company’s stocks as collateral again the loans. As of June 30, 2024, total stocks pledged with the long-term loans is 32,656,840 shares. As of June 30, 2024, long term loan consisted of the following: Shares Principal Accrued Balance Received long term loan on April 27, 2021 10,000,000 $ 200,000 $ 127,123 $ 327,123 Received long term loan on June 3, 2021 3,050,000 290,000 178,449 468,449 Received long term loan on June 4, 2021 500,000 50,000 30,767 80,767 Received long term loan on June 23, 2021 300,000 30,000 18,132 48,132 Received long term loan on July 12, 2021 80,000 10,000 5,940 15,940 Received long term loan on September 1, 2021 1,540,000 60,000 33,962 93,962 Received long term loan on September 22, 2021 500,000 50,000 27,726 77,726 Received long term loan on September 27, 2021 500,000 50,000 27,589 77,589 Received long term loan on October 29, 2021 161,840 12,138 6,485 18,623 Received long term loan on November 9, 2021 500,000 50,000 26,411 76,411 Received long term loan on November 16, 2021 1,400,000 140,000 73,414 213,414 Received long term loan on November 18, 2021 500,000 50,000 26,164 76,164 Received long term loan on November 29, 2021 200,000 20,000 10,345 30,345 Received long term loan on November 30, 2021 100,000 10,000 5,167 15,167 Received long term loan on October 13, 2022 2,625,000 21,000 7,203 28,203 Received long term loan on March 10, 2023 1,000,000 10,000 2,620 12,620 Received long term loan on March 14, 2023 1,000,000 10,000 2,597 12,597 Received long term loan on March 16, 2023 1,000,000 10,000 2,586 12,586 Received long term loan on April 17, 2023 6,000,000 30,000 7,233 37,233 Received long term loan on May 9, 2023 1,000,000 10,000 2,290 12,290 Received long term loan on June 24, 2021 600,000 60,000 38,236 98,236 Total 32,556,840 $ 1,173,138 $ 660,439 $ 1,833,577 The principal balance, the scheduled principal payments, the schedule interest payments, and the weighted average interest rates of the long-term loan future maturities are as follows: Year Ending June 30 Principal Scheduled Schedule Weighted 2025 1,173,138 - 234,628 20.00 % 2026 473,138 700,000 112,883 9.62 % 2027 21,000 452,138 67,413 14.25 % 2028 - 21,000 3,057 14.56 %

CONVERTIBLE, REDEEMABLE PREFERR

CONVERTIBLE, REDEEMABLE PREFERRED STOCK	12 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
CONVERTIBLE, REDEEMABLE PREFERRED STOCK	NOTE 7 CONVERTIBLE, REDEEMABLE PREFERRED STOCK During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for the purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change. In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000. There were no preferred shares outstanding as of June 30, 2024 and 2023.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	NOTE 8 – STOCK BASED COMPENSATION The Company sometimes issues common stock to employees, contractors and consultants for services rendered. The Company accounts for stock-based payments to employees, contractors and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense. The Company recognizes the fair value of stock-based compensation awards in payroll if it is for employees, and operating costs if it is for contractors and consultants, as appropriate, in the Company’s consolidated statements of operations. The Company issued 11,370,178 shares to one of its employees as stock compensation during the year of 2024, total amount of $123,582.

TREASURY STOCK SHARES

TREASURY STOCK SHARES	12 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
TREASURY STOCK SHARES	NOTE 9 TREASURY STOCK SHARES On January 22, 2024, the Company issued 52,100,000 shares of common stock to Top Professional Management Group Inc. in exchange for 51% of the control shares. However, due to the incomplete internal due diligence process, the investment was temporarily suspended, and the Board of Directors withheld the certificate for further evaluation. As a result, the Company recorded 52,100,000 shares of common stock as treasury stock as of June 30, 2024.

SHAREHOLDERS' DEFICIT

SHAREHOLDERS' DEFICIT	12 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' DEFICIT	NOTE 10 SHAREHOLDERS’ DEFICIT On June 30, 2024 and 2023, the Company had 21,136,888,326 and 21,107,018,148 shares of common stock issued and outstanding, respectively. 1) Shares issued for equity investment On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date. Equity Investments: On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd (“Purecell”) in exchange for 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed an agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue an additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholders of AP, at fair market value of $0.00001 per share. On March 31, 2022, the Company issued 1,300,000 shares of common stock to an US individual at $0.075 per share. On November 22, 2023, the Company issued 8,000,000 shares of common stock at $0.010 per share to four investors. On November 24, 2023, the Company issued 1,000,000 shares of common stock at $0.020 per share to one investor. On January 2, 2024, the Company issued 1,000,000 shares of common stock at $0.010 per share to one investor. On January 16, 2024, the Company issued 500,000 shares of common stock at $0.010 per share to one investor. On January 22, 2024, the Company issued 52,100,000 shares of common stock to Top Professional Management Group Inc. for its 51% of control shares. However, due to the incomplete internal due diligence process, the investment was temporarily suspended, and the Board of Directors withheld the certificate for further evaluation. These shares are held in treasury. 2) Shares issued for stock compensation On October 30, 2023, the Company issued an aggregate of 6,488,867 shares of common stock to three unrelated parties as compensation for services. The issuance of these shares is recorded at a fair market value of $25,956. On January 22, 2024, the Company issued 4,881,311 shares of common stock to an unrelated party as compensation for services. The issuance of these shares is recorded at a fair market value of $97,626. 3) Shares issued for loans as original issue discount On October 30, 2023, the Company issued 7,000,000 shares of restricted common stock free to three unrelated parties’ long-term loans (three years) of $40,000. The issuance of these shares is as the collateral of the corresponding loans and is recorded at a fair market value of $28,000 or at $0.02 per share. On January 22, 2024, the Company issued 1,000,000 shares of restricted common stock free to an unrelated party to extend a short-term loan (six month) of $40,000 dated March 1, 2023. The issuance of these shares is recorded at a fair market value of $20,000 or at $0.02 per share.

EQUITY INVESTMENT

EQUITY INVESTMENT	12 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
EQUITY INVESTMENT	NOTE 11 EQUITY INVESTMENT On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd (“Purecell” ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed an agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. The following table summarizes the income statement of Purecell. From date of From date of equity equity Investment investment 06/30/2024 06/30/2023 Sales $ 61,457 $ 270,931 Gross profit 61,457 246,441 Net loss (294,904 ) (307,359 ) 51% share $ (150,401 ) $ (156,753 ) The following table provides the summary of balance sheet information for Purecell. Because the 51% of Purecell losses exceeded the investment the Company made to Purecell, the value of investment is zero, As of As of 2024 2023 Total assets $ 3,092,663 $ 3,192,224 Net assets 2,021,541 2,203,484 51% ownership 1,030,986 1,231,113 Beginning balance of investment, May 11, 2021 5,450 5,450 Loss on equity investment - accumulated (5,450 ) (5,450 ) Ending balance of investment, June 30, 2024 -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 12 INCOME TAXES Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards. As of June 30, 2024, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset. Under the Provisional Regulations of The People’s Republic of China Concerning Income Tax on Enterprises promulgated by the PRC, which took effect on January 1, 2008, domestic and foreign companies pay a unified corporate income tax of 25%, except for a 15% corporate income tax rate for qualified high technology and science enterprises. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2024 and 2023 as follows: Year Ended June 30, 2024 2023 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )% The components of deferred taxes consist of the following at June 30, 2024 and 2023: June 30, June 30, Net operating loss carryforwards $ 7,924,234 $ 6,697,872 Less: valuation allowance (7,924,234 ) (6,697,872 ) Net deferred tax assets $ - $ - As of June 30, 2024, the Company had federal and California income tax net operating loss carryforwards of $7,924,234. These net operating losses originating in tax years beginning prior to Jan. 1, 2018, will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018, will be carried forwarded indefinitely.

LEASE

LEASE	12 Months Ended
	Jun. 30, 2024
Disclosure Text Block [Abstract]
LEASE	NOTE 13 LEASE The Company has a month-to-month leases agreement with GKT, Alhambra, LP after the prior lease expired on November 30, 2023. The current monthly rent including monthly management fee is $4,939.17. The Company has entered into an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from June 1, 2024 to May 31, 2026 after the prior lease expired on May 31, 2024. The current monthly rent including monthly management fee is $1,940.40. The operating lease is listed as a separate line item on the Company’s consolidated financial statements and represents the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments is also listed as a separate line item on the Company’s condensed consolidated financial statements. Operating lease right-of-use assets and liabilities commencing are recognized at commencement date based on the present value of lease payments over the lease term. For the year ended June 30, 2024, the Company recognized approximately $80,438 in total lease costs. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended June 30, Cash paid for operating lease liabilities $ 80,438 Weighted-average remaining lease term 1.92 Weighted-average discount rate 5 % Minimum future lease payments $ 45,475 The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2025 $ 23,355 2026 22,120 Total minimum payments 45,475 Less: imputed interest (2,215 ) Total lease liability 43,260 Less: short-term lease liability (21,683 ) Long-term lease liability $ 21,577

CONCENTRATION

CONCENTRATION	12 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
CONCENTRATION	NOTE 14 CONCENTRATION Major vendors For the year ended June 30, 2024, no vendors accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balances as at year-end dates.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 SUBSEQUENT EVENTS On August 26, 2024, America Great Health (the “Company”) entered into an International Agency Agreement (the “Agreement”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under this Agreement, the Company has appointed Yunchi as its exclusive agent to promote and sell Ionic Peptide products within Yunnan Province, China, for a term of three years. According to the Agreement, the target sales are set at $1 million for the first year following the execution of the Agreement, with $5 million targeted for both the second and third years. Furthermore, Yunchi holds the exclusive rights to market and sell the products within Yunnan Province during the contract term. Form 8-K for this agreement was released on August 30, 2024 On September 02, 2024, the International Institute of Great Health, Inc. (the “Company”), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the “Contract”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its ionic peptide project using liquor distiller’s grains and will compensate the Company for these services. The development involves the Company’s proprietary, patented protein peptide surface ion modification, transformation, and activation technology, which will be applied to Yunchi’s existing liquor tank raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on September 9, 2024. On September 02, 2024, the International Institute of Great Health, Inc. (the “Company”), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the “Contract”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its Ganoderma lucidum ionic peptide project and will compensate the Company for these services. The development involves the Company’s proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi’s existing Ganoderma lucidum raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on September 16, 2024. On September 16, 2024, the International Institute of Great Health, Inc. (the “Company”), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the “Contract”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its bird’s nest ionic peptide project and will compensate the Company for these services. The development involves the Company’s proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi’s existing bird’s nest raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for two and a half (2.5) months. Form 8-K for this contract was released on September 25, 2024. On September 22, 2024, America Great Health (the “Company”) entered into a Framework Agreement for Product Project Cooperation (the “Contract”) with Aide Huhuan (Chengdu) Enterprise Management, Co. Ltd., a Chinese company (“Aide Huhuan”). The Company’s products are a series of ion peptide products developed using “protein surface ion modification technology,” achieving a world-leading position in both research and production. Aide Huhuan, with its strategic location in Chengdu, China, has the advantage of nationwide market reach, including access to multiple hospital preparation channels and an extensive marketing network. Under the Contract, Aide Huhuan will utilize its market resources to promote and sell the ion protein peptide products developed by the Company, thereby expanding market share. Both parties will collaborate on technical exchanges and cooperation in the field of biotechnology. The Company guarantees that its products meet the necessary compliance qualifications for entry into the Chinese market and will provide high-quality ion protein peptide products that adhere to relevant standards. Additionally, the Company will offer Aide Huhuan product training and technical support to help them effectively promote and sell the products in China. Form 8-K for this contract was released on September 30, 2024. On September 24, 2024, the International Institute of Great Health, Inc. (the “Company”), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the “Contract”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its Panax notoginseng peptide project and will compensate the Company for these services. The development involves the Company’s proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi’s existing Panax notoginseng peptide raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on October 4, 2024. On September 20, 2024, the International Institute of Great Health, Inc. (the “Company”), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the “Contract”) with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company (“Yunchi”). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its sea cucumber ion peptide project and will compensate the Company for these services. The development involves the Company’s proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi’s existing sea cucumber raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro. According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months. Form 8-K for this contract was released on October 8, 2024. From August 9, 2024 to September 15, 2024, one investor paid $68,000 to purchase 5,200,000 common shares. The transfer agent has not issued these shares until the issuance of this report. On October 30, 2024, another investor paid $9,116 to purchase 1,823,282 common shares. The transfer agent has not issued these shares until the issuance of this report. On September 20, 2024, the Company signed a service agreement of fund-raising service with an unrelated person and beside the service fees of $8,000, he will receive 6,800,000 common shares as a bonus.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,220,571)	$ (761,420)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company has adjusted certain previously reported amounts in its balance sheets as of and for the year ended June 30, 2023 to reflect the recording of the advances from customers, netting the corresponding accumulated deficit for an amount of $155,000 which was originally recognized as revenue. This adjustment did not materially impact the financial position and the result of operations of the Company for the year indicated.
Basis of Consolidation	Basis of Consolidation The Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), US-China Mega Beauty Health Industry Development Co., LTD, (100%), and Peptide Life Inc in California (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Peptide Life Inc in California USA 100
Estimates	Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ deficit. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of Meizhong Health Industry Development Co., Ltd. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) 2024 Chinese Renminbi (RMB) RMB 7.2139 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) 2024 Chinese Renminbi (RMB) RMB 7.2674 United States dollar ($) $ 1.00
Reclassification of Prior Year Presentations	Reclassification of Prior Year Presentations Certain prior year accounts and amounts have been reclassified for consistency with the current year presentation. These reclassifications have no effect on the reported results of operations. Below is the comparison of the reclassification and the original representation of the related accounts and amounts. Consolidated Balance Sheet Reclassified Original June 30, June 30, 2023 Short term loan $ 727,003 $ 705,216 Accrued liabilities 186,455 609,892 Deferred income - 223,331 Advances from customers 68,331 - Long term loan 1,524,788 1,123,138 Accumulated deficit (9,028,110 ) (9,183,110 ) Total $ (6,521,533 ) (6,521,533 ) Consolidated Statement of Cash Flows Reclassified Original June 30, 2023 June 30, 2023 Proceed from issuance of common stocks $ 26,200 $ 92,080 Payment of leases and rent (75,706 ) - Right of use asset – net 51,968 - Lease liabilities – net 23,738 - Stock based comprehension 65,880 - Short term loan - 521,284 Short term loan – proceeds 565,216 - Short term loan – repayment (43,932 ) - Accrued interest for short term loan 59,356 - Short term loan – interest paid (59,356 ) - Income tax payable 800 - Other payable (89,259 ) (88,459 ) Long term loan - 324,682 Long term loan – proceeds 91,000 - Accrued interest for long term loan 237,857 - Long term loan – interest paid (4,175 ) - Advances from related parties 224,422 (148,718 ) Repayment to related parties (373,140 ) - Total $ 700,869 $ 700,869
Cash	Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2024 and 2023, the Company’s bank account in the United States had $9,355 and $4,131, respectively, under FDIC insurance of $250,000.
Revenues	Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health-related products through wholesale and retailers. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company usually does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date and 180 days for a major customer, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted on the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time when shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. Any payment received prior to shipment is recognized as a contract liability under the account deferred revenue. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed by third-party carriers for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in the cost of sales for all periods presented.
Account Receivable	Account Receivable The Company has been developing its new products and launching large-scale production since November 2023. As of June 30, 2024 net accounts receivable amounted to $55,100. The Company has not established a reserve for uncollectible amounts on the newly launched products since the historical data on bad debts in the aging categories of the new products could not support such estimates. For the year ended June 30, 2024, the Company has $23,400 of allowance for bad debt.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the year ended June 30, 2024, the Company has $9,400 of inventory valuation reserve. At the end of fiscal years 2024 and 2023, inventories comprised: June 30, June 30, Raw materials $ 56,435 $ 62,348 Finished goods 36,106 46,003 Inventory valuation reserve (9,400 ) - Subtotal $ 83,141 $ 108,351
Cost of Goods Sold	Cost of Goods Sold The cost of goods sold includes product costs only and is recorded in the same period in which related revenues have been recorded.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Machinery and equipment 5 years At the end of fiscal years 2024 and 2023, machinery and equipment at cost and accumulated depreciation were: June 30, June 30, Machinery and equipment $ 73,943 $ 73,943 Accumulated depreciation (31,040 ) (16,251 ) Subtotal $ 42,903 $ 57,692
Equity Method Investments	Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.
Fair Value Measurements	Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.
Stock-based Compensations	Stock-based Compensations The Company offers restricted stock-based compensations to the employees and contractors. All stock-based compensations are measured based on their values and are expensed over the period during which an employee or a contractor is required to provide service in exchange for the compensations.
Treasury Stock Shares	Treasury Stock Shares Treasury shares are recognized at acquisition cost and are presented as a deduction from shareholder’s equity. Upon sale of treasury shares, the realized gain or loss is recognized through the income statement as income or expense from financial assets.
Loss Per Share	Loss Per Share Basic earnings (loss) per share are computed by dividing the income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2024 and 2023, as there are no potential shares outstanding that would have a diluted effect.
Income Taxes	Income Taxes Income tax expenses are based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2023, the FASB issued Accounting Standard Update (“ASU”) No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation (Topic 718). As ASU 2023-03 did not provide any new guidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance. The adoption of ASU 2023-03 did not have any impact on the Company’s consolidated financial statement presentation or related disclosures. In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), Income Taxes (Topic 740): Improvements to Income Tax Disclosures to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. As the amendments apply to income tax disclosures only, the Company does not expect adoption to have a material impact on our consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Subsidiaries	The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Peptide Life Inc in California USA 100
Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount	Below is a table with foreign exchange rates used for translation: June 30, Average Yearly (average rate) 2024 Chinese Renminbi (RMB) RMB 7.2139 United States dollar ($) $ 1.00 June 30, Year Ended (Closing rate) 2024 Chinese Renminbi (RMB) RMB 7.2674 United States dollar ($) $ 1.00
Schedule of Consolidated Balance Sheet	Consolidated Balance Sheet Reclassified Original June 30, June 30, 2023 Short term loan $ 727,003 $ 705,216 Accrued liabilities 186,455 609,892 Deferred income - 223,331 Advances from customers 68,331 - Long term loan 1,524,788 1,123,138 Accumulated deficit (9,028,110 ) (9,183,110 ) Total $ (6,521,533 ) (6,521,533 )
Schedule of Consolidated Statement of Cash Flows	Consolidated Statement of Cash Flows Reclassified Original June 30, 2023 June 30, 2023 Proceed from issuance of common stocks $ 26,200 $ 92,080 Payment of leases and rent (75,706 ) - Right of use asset – net 51,968 - Lease liabilities – net 23,738 - Stock based comprehension 65,880 - Short term loan - 521,284 Short term loan – proceeds 565,216 - Short term loan – repayment (43,932 ) - Accrued interest for short term loan 59,356 - Short term loan – interest paid (59,356 ) - Income tax payable 800 - Other payable (89,259 ) (88,459 ) Long term loan - 324,682 Long term loan – proceeds 91,000 - Accrued interest for long term loan 237,857 - Long term loan – interest paid (4,175 ) - Advances from related parties 224,422 (148,718 ) Repayment to related parties (373,140 ) - Total $ 700,869 $ 700,869
Schedule of Inventory	At the end of fiscal years 2024 and 2023, inventories comprised: June 30, June 30, Raw materials $ 56,435 $ 62,348 Finished goods 36,106 46,003 Inventory valuation reserve (9,400 ) - Subtotal $ 83,141 $ 108,351
Schedule of Property and Equipment	Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Machinery and equipment 5 years June 30, June 30, Machinery and equipment $ 73,943 $ 73,943 Accumulated depreciation (31,040 ) (16,251 ) Subtotal $ 42,903 $ 57,692

OTHER ASSET (Tables)

OTHER ASSET (Tables)	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	As of June 30, 2024 and 2023, other assets amounted to $11,836 for both years. Other assets consist of the following: June 30, June 30, Rent deposits 11,836 11,836 Total 11,836 11,836

SHORT TERM LOAN (Tables)

SHORT TERM LOAN (Tables)	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Short Term Loan	Short Term Loans As of June 30, 2024 As of June 30, 2023 Receiving Maturity Principal Accrued Total Principal Accrued Total 2024 1/13/2023 1/13/2024 $ -- $ 27,200 $ 27,200 $ 150,000 $ 5,809 $ 155,809 20 % 1/19/2023 1/18/2024 300,000 39,028 339,028 300,000 15,978 315,978 13 % 2/6/2023 7/2/2024 750 - 750 15,216 - 15,216 316 % 2/25/2023 6/24/2023 100,000 - 100,000 100,000 - 100,000 24 % 3/1/2023 8/31/2023 10,000 - 10,000 10,000 - 10,000 20 % 3/1/2023 8/31/2023 50,000 - 50,000 50,000 - 50,000 20 % 3/1/2023 9/30/2023 30,000 - 30,000 30,000 - 30,000 10 % 3/1/2023 9/30/2023 50,000 - 50,000 50,000 - 50,000 10 % Total $ 540,750 $ 66,228 $ 606,978 $ 705,216 $ 21,787 $ 727,003

LONG TERM LOAN (Tables)

LONG TERM LOAN (Tables)	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	As of June 30, 2024, long term loan consisted of the following: Shares Principal Accrued Balance Received long term loan on April 27, 2021 10,000,000 $ 200,000 $ 127,123 $ 327,123 Received long term loan on June 3, 2021 3,050,000 290,000 178,449 468,449 Received long term loan on June 4, 2021 500,000 50,000 30,767 80,767 Received long term loan on June 23, 2021 300,000 30,000 18,132 48,132 Received long term loan on July 12, 2021 80,000 10,000 5,940 15,940 Received long term loan on September 1, 2021 1,540,000 60,000 33,962 93,962 Received long term loan on September 22, 2021 500,000 50,000 27,726 77,726 Received long term loan on September 27, 2021 500,000 50,000 27,589 77,589 Received long term loan on October 29, 2021 161,840 12,138 6,485 18,623 Received long term loan on November 9, 2021 500,000 50,000 26,411 76,411 Received long term loan on November 16, 2021 1,400,000 140,000 73,414 213,414 Received long term loan on November 18, 2021 500,000 50,000 26,164 76,164 Received long term loan on November 29, 2021 200,000 20,000 10,345 30,345 Received long term loan on November 30, 2021 100,000 10,000 5,167 15,167 Received long term loan on October 13, 2022 2,625,000 21,000 7,203 28,203 Received long term loan on March 10, 2023 1,000,000 10,000 2,620 12,620 Received long term loan on March 14, 2023 1,000,000 10,000 2,597 12,597 Received long term loan on March 16, 2023 1,000,000 10,000 2,586 12,586 Received long term loan on April 17, 2023 6,000,000 30,000 7,233 37,233 Received long term loan on May 9, 2023 1,000,000 10,000 2,290 12,290 Received long term loan on June 24, 2021 600,000 60,000 38,236 98,236 Total 32,556,840 $ 1,173,138 $ 660,439 $ 1,833,577
Schedule of Maturities of Long-Term Debt	The principal balance, the scheduled principal payments, the schedule interest payments, and the weighted average interest rates of the long-term loan future maturities are as follows: Year Ending June 30 Principal Scheduled Schedule Weighted 2025 1,173,138 - 234,628 20.00 % 2026 473,138 700,000 112,883 9.62 % 2027 21,000 452,138 67,413 14.25 % 2028 - 21,000 3,057 14.56 %

EQUITY INVESTMENT (Tables)

EQUITY INVESTMENT (Tables)	12 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments	The following table summarizes the income statement of Purecell. From date of From date of equity equity Investment investment 06/30/2024 06/30/2023 Sales $ 61,457 $ 270,931 Gross profit 61,457 246,441 Net loss (294,904 ) (307,359 ) 51% share $ (150,401 ) $ (156,753 ) As of As of 2024 2023 Total assets $ 3,092,663 $ 3,192,224 Net assets 2,021,541 2,203,484 51% ownership 1,030,986 1,231,113 Beginning balance of investment, May 11, 2021 5,450 5,450 Loss on equity investment - accumulated (5,450 ) (5,450 ) Ending balance of investment, June 30, 2024 -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2024 and 2023 as follows: Year Ended June 30, 2024 2023 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )%
Schedule of Deferred Tax Assets and Liabilities	The components of deferred taxes consist of the following at June 30, 2024 and 2023: June 30, June 30, Net operating loss carryforwards $ 7,924,234 $ 6,697,872 Less: valuation allowance (7,924,234 ) (6,697,872 ) Net deferred tax assets $ - $ -

LEASE (Tables)

LEASE (Tables)	12 Months Ended
	Jun. 30, 2024
Disclosure Text Block [Abstract]
Lease, Cost	Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended June 30, Cash paid for operating lease liabilities $ 80,438 Weighted-average remaining lease term 1.92 Weighted-average discount rate 5 % Minimum future lease payments $ 45,475
Lessee, Operating Lease, Liability, Maturity	The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2025 $ 23,355 2026 22,120 Total minimum payments 45,475 Less: imputed interest (2,215 ) Total lease liability 43,260 Less: short-term lease liability (21,683 ) Long-term lease liability $ 21,577

NATURE OF BUSINESS (Details)

NATURE OF BUSINESS (Details)

1 Months Ended

12 Months Ended

Jan. 22, 2024 shares

Jan. 16, 2024 shares

Jan. 02, 2024 shares

Nov. 24, 2023 shares

Nov. 22, 2023 shares

Nov. 25, 2022

Apr. 20, 2022 shares

Mar. 31, 2022 shares

Nov. 11, 2021 $ / shares shares

Sep. 03, 2021 USD ($)

Jul. 09, 2021 USD ($)

Dec. 07, 2020 USD ($)

Jun. 30, 2020 shares

Jan. 19, 2017 USD ($) shares

Jul. 31, 2021 USD ($)

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Nov. 26, 2022 USD ($)

Jun. 30, 2022 USD ($)

Nov. 15, 2021 shares

Nov. 04, 2021

Apr. 06, 2021

Feb. 04, 2021

NATURE OF BUSINESS (Details) [Line Items]

Stock Issued During Period, Shares, Acquisitions (in Shares) | shares

510,000,000

16,155,746,000

Proceeds from Sales of Business, Affiliate and Productive Assets

$ 100

Payments to Acquire Investments

$ 50,000

Number of Units in Real Estate Property

53

Number of Real Estate Properties

19

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross

$ 7,626,286.37

Payments to Acquire Real Estate

$ 7,000,000

Real Estate, Description of Terms

The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.

Class of Warrant or Rights, Granted (in Shares) | shares

500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Warrants and Rights Outstanding, Term

24 months

Stock Issued During Period, Shares, New Issues (in Shares) | shares

52,100,000

500,000

1,000,000

1,000,000

8,000,000

500,000

1,300,000

Investment Owned, Balance, Shares (in Shares) | shares

20,000,000

Agreement, Description

The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai’s successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.

Other Commitment

$ 34,978.48

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

$ (1,226,362)

$ (777,340)

Net Cash Provided by (Used in) Operating Activities

(615,627)

(389,809)

Equity, Including Portion Attributable to Noncontrolling Interest

(5,311,599)

(4,370,836)

$ (3,705,481)

Cash

$ 54,943

$ 54,150

Corporate Joint Venture [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 4,200,000

Co-venturer [Member]

NATURE OF BUSINESS (Details) [Line Items]

Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)

$ 100,000

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Subsidiary, Ownership Percentage, Parent

75%

Investment Owned, Balance, Shares (in Shares) | shares

60,000,000

Subsidiary, Ownership Percentage, Noncontrolling Owner

25%

Purecell Group [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

51%

51%

51%

JV Company [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

60%

Brilliant Healthcare Limited [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

40%

Nutrature Health LLC [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

100%

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

International Institute of Great Health, Inc. (IIGH) [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

Common Stock [Member] | Co-venturer [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 15,000,000

Cash Distribution [Member] | Co-venturer [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 3,000,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Nov. 04, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Retained Earnings (Accumulated Deficit)	$ (10,248,681)	$ (9,028,110)
Cash, Uninsured Amount	9,355	4,131
Cash, FDIC Insured Amount	250,000
Accounts Receivable, after Allowance for Credit Loss, Current	55,100	0
Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss	23,400
Inventory Valuation Reserves	$ 9,400	0
Revision of Prior Period, Error Correction, Adjustment [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Retained Earnings (Accumulated Deficit)		$ 155,000
America Great Health California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
GOF Biotechnologies in California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	75%
International Institute of Great Health [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
Nutrature Health LLC [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%		100%
Sijinsai [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
Peptide Life Inc in California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Subsidiaries (Details)	12 Months Ended
	Jun. 30, 2024	Nov. 04, 2021
America Great Health California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
GOF Biotechnologies in California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	75%
International Institute of Great Health [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
Nutrature Health LLC [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%	100%
Sijinsai [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	100%
Peptide Life Inc in California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount (Details)	Jun. 30, 2024
China, Yuan Renminbi | Income Statement Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	7.2139
United States of America, Dollars | Income Statement Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	1
United States of America, Dollars | Balance Sheet Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	1
Balance Sheet Items [Member] | China, Yuan Renminbi
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	7.2674

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Consolidated Balance Sheet (Details)	Jun. 30, 2023 USD ($)
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Short term loan	$ 727,003
Accrued liabilities	186,455
Deferred income	0
Advances from customers	68,331
Long term loan	1,524,788
Accumulated deficit	(9,028,110)
Total	(6,521,533)
Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Short term loan	705,216
Accrued liabilities	609,892
Deferred income	223,331
Advances from customers	0
Long term loan	1,123,138
Accumulated deficit	(9,183,110)
Total	$ (6,521,533)

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Consolidated Statement of Cash Flows (Details)	12 Months Ended
	Jun. 30, 2023 USD ($)
Revision of Prior Period, Adjustment [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Consolidated Statement of Cash Flows (Details) [Line Items]
Proceed from issuance of common stocks	$ 26,200
Payment of leases and rent	(75,706)
Right of use asset – net	51,968
Lease liabilities – net	23,738
Stock based comprehension	65,880
Short term loan	0
Short term loan – proceeds	565,216
Short term loan – repayment	(43,932)
Accrued interest for short term loan	59,356
Short term loan – interest paid	(59,356)
Income tax payable	800
Other payable	(89,259)
Long term loan	0
Long term loan – proceeds	91,000
Accrued interest for long term loan	237,857
Long term loan – interest paid	(4,175)
Advances from related parties	224,422
Repayment to related parties	(373,140)
Total	700,869
Previously Reported [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Consolidated Statement of Cash Flows (Details) [Line Items]
Proceed from issuance of common stocks	92,080
Payment of leases and rent	0
Right of use asset – net	0
Lease liabilities – net	0
Stock based comprehension	0
Short term loan	521,284
Short term loan – proceeds	0
Short term loan – repayment	0
Accrued interest for short term loan	0
Short term loan – interest paid	0
Income tax payable	0
Other payable	(88,459)
Long term loan	324,682
Long term loan – proceeds	0
Accrued interest for long term loan	0
Long term loan – interest paid	0
Advances from related parties	(148,718)
Repayment to related parties	0
Total	$ 700,869

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Inventories Abstract
Raw materials	$ 56,435	$ 62,348
Finished goods	36,106	46,003
Inventory valuation reserve	(9,400)	0
Subtotal	$ 83,141	$ 108,351

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ (31,040)	$ (16,251)
Subtotal	$ 42,903	57,692
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Machinery and equipment estimated useful lives	5 years
Machinery and equipment	$ 73,943	$ 73,943

OTHER ASSET (Details)

OTHER ASSET (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Receivables [Abstract]
Other Receivables	$ 11,836	$ 11,836

OTHER ASSET - Schedule of Accou

OTHER ASSET - Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Accounts Notes Loans And Financing Receivable Abstract
Rent deposits	$ 11,836	$ 11,836
Total	$ 11,836	$ 11,836

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Majority Shareholder [Member] - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt	$ 969,868
Repayments of Related Party Debt	276,596
Notes Payable	$ 1,110,196	$ 425,142
Imputed Interest		$ 5,205

SHORT TERM LOAN (Details)

SHORT TERM LOAN (Details) - Short-Term Debt [Member] - USD ($)	Jun. 30, 2024	Jun. 30, 2023
SHORT TERM LOAN (Details) [Line Items]
Short-Term Debt	$ 540,750	$ 705,216
Deposits Received for Securities Loaned, at Carrying Value	$ 150,000

SHORT TERM LOAN - Schedule of S

SHORT TERM LOAN - Schedule of Short Term Loan (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Short-Term Debt [Line Items]
Principal	$ 540,750	$ 705,216
Accrued Interest Liability	66,228	21,787
Total	$ 606,978	727,003
Annualized percentage rate	20%
Loan Received on January 13, 2023 [Member]
Short-Term Debt [Line Items]
Maturity Date	Jan. 13, 2024
Principal	$ 0	150,000
Accrued Interest Liability	27,200	5,809
Total	$ 27,200	155,809
Annualized percentage rate	20%
Loan Received on January 19, 2023 [Member]
Short-Term Debt [Line Items]
Maturity Date	Jan. 18, 2024
Principal	$ 300,000	300,000
Accrued Interest Liability	39,028	15,978
Total	$ 339,028	315,978
Annualized percentage rate	13%
Loan Received on February 6, 2023 [Member]
Short-Term Debt [Line Items]
Maturity Date	Jul. 02, 2024
Principal	$ 750	15,216
Accrued Interest Liability	0	0
Total	$ 750	15,216
Annualized percentage rate	316%
Loan Received on February 25, 2023 [Member]
Short-Term Debt [Line Items]
Maturity Date	Jun. 24, 2023
Principal	$ 100,000	100,000
Accrued Interest Liability	0	0
Total	$ 100,000	100,000
Annualized percentage rate	24%
Loan Received on March 01, 2023 [Member]
Short-Term Debt [Line Items]
Maturity Date	Aug. 31, 2023
Principal	$ 10,000	10,000
Accrued Interest Liability	0	0
Total	$ 10,000	10,000
Annualized percentage rate	20%
Loan Received on March 01, 2023 1 [Member]
Short-Term Debt [Line Items]
Maturity Date	Aug. 31, 2023
Principal	$ 50,000	50,000
Accrued Interest Liability	0	0
Total	$ 50,000	50,000
Annualized percentage rate	20%
Loan Received on March 01, 2023 2 [Member]
Short-Term Debt [Line Items]
Maturity Date	Sep. 30, 2023
Principal	$ 30,000	30,000
Accrued Interest Liability	0	0
Total	$ 30,000	30,000
Annualized percentage rate	10%
Loan Received on March 01, 2023 3 [Member]
Short-Term Debt [Line Items]
Maturity Date	Sep. 30, 2023
Principal	$ 50,000	50,000
Accrued Interest Liability	0	0
Total	$ 50,000	$ 50,000
Annualized percentage rate	10%

LONG TERM LOAN (Details)

LONG TERM LOAN (Details) - USD ($)		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2024	Jun. 30, 2023
LONG TERM LOAN (Details) [Line Items]
Proceeds from Issuance of Debt		$ 1,173,138	$ 1,123,138
Debt Instrument, Interest Rate, Stated Percentage		20%
Long-Term Debt, Term		5 years
Interest Expense, Debt		$ 660,439
Loan Received		$ 10,000
Proceeds from Interest Received	$ 3,000
Stocks pledged with the long-term loans (in Shares)		32,656,840
Loans Payable [Member]
LONG TERM LOAN (Details) [Line Items]
Interest Expense, Debt		$ 222,745	$ 212,704

LONG TERM LOAN - Schedule of Lo

LONG TERM LOAN - Schedule of Long-term Debt Instruments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2028	Dec. 31, 2027	Dec. 31, 2026	Jun. 30, 2025
Debt Instrument [Line Items]
Shares pledged (in Shares)	32,556,840
Principal	$ 1,173,138	$ 1,123,138
Accrued interest liability	660,439
Balance	$ 1,833,577		$ 0	$ 21,000	$ 473,138	$ 1,173,138
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	10,000,000
Principal	$ 200,000
Accrued interest liability	127,123
Balance	$ 327,123
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	3,050,000
Principal	$ 290,000
Accrued interest liability	178,449
Balance	$ 468,449
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	500,000
Principal	$ 50,000
Accrued interest liability	30,767
Balance	$ 80,767
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	300,000
Principal	$ 30,000
Accrued interest liability	18,132
Balance	$ 48,132
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	80,000
Principal	$ 10,000
Accrued interest liability	5,940
Balance	$ 15,940
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,540,000
Principal	$ 60,000
Accrued interest liability	33,962
Balance	$ 93,962
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	500,000
Principal	$ 50,000
Accrued interest liability	27,726
Balance	$ 77,726
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	500,000
Principal	$ 50,000
Accrued interest liability	27,589
Balance	$ 77,589
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	161,840
Principal	$ 12,138
Accrued interest liability	6,485
Balance	$ 18,623
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	500,000
Principal	$ 50,000
Accrued interest liability	26,411
Balance	$ 76,411
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,400,000
Principal	$ 140,000
Accrued interest liability	73,414
Balance	$ 213,414
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	500,000
Principal	$ 50,000
Accrued interest liability	26,164
Balance	$ 76,164
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	200,000
Principal	$ 20,000
Accrued interest liability	10,345
Balance	$ 30,345
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	100,000
Principal	$ 10,000
Accrued interest liability	5,167
Balance	$ 15,167
Loan Received on October 13, 2022 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	2,625,000
Principal	$ 21,000
Accrued interest liability	7,203
Balance	$ 28,203
Loan Received on March 10, 2023 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,000,000
Principal	$ 10,000
Accrued interest liability	2,620
Balance	$ 12,620
Loan Received on March 14, 2023 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,000,000
Principal	$ 10,000
Accrued interest liability	2,597
Balance	$ 12,597
Loan Received on March 16, 2023 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,000,000
Principal	$ 10,000
Accrued interest liability	2,586
Balance	$ 12,586
Loan Received on April 17, 2023 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	6,000,000
Principal	$ 30,000
Accrued interest liability	7,233
Balance	$ 37,233
Loan Received on May 9, 2023 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	1,000,000
Principal	$ 10,000
Accrued interest liability	2,290
Balance	$ 12,290
Loan Received on June 24, 2021 [Member]
Debt Instrument [Line Items]
Shares pledged (in Shares)	600,000
Principal	$ 60,000
Accrued interest liability	38,236
Balance	$ 98,236

LONG TERM LOAN - Schedule of _2

LONG TERM LOAN - Schedule of Long-term Debt Instruments (Parentheticals) (Details)	12 Months Ended
	Jun. 30, 2024
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Apr. 27, 2021
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 03, 2021
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 04, 2021
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 23, 2021
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jul. 12, 2021
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 01, 2021
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 22, 2021
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 27, 2021
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Oct. 29, 2021
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 09, 2021
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 16, 2021
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 18, 2021
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 29, 2021
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Nov. 30, 2021
Loan Received on October 13, 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Oct. 13, 2022
Loan Received on March 10, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 10, 2023
Loan Received on March 14, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 14, 2023
Loan Received on March 16, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Mar. 16, 2023
Loan Received on April 17, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Apr. 17, 2023
Loan Received on May 9, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 09, 2023
Loan Received on June 24, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 24, 2021

LONG TERM LOAN - Schedule of Ma

LONG TERM LOAN - Schedule of Maturities of Long-Term Debt (Details) - USD ($)	12 Months Ended	18 Months Ended
	Jun. 30, 2025	Dec. 31, 2028	Dec. 31, 2027	Dec. 31, 2026	Jun. 30, 2024
Schedule Of Maturities Of Long Term Debt Abstract
Principal Balance	$ 1,173,138	$ 0	$ 21,000	$ 473,138	$ 1,833,577
Scheduled Principal Payments	0	21,000	452,138	700,000
Schedule Interest Payments	$ 234,628	$ 3,057	$ 67,413	$ 112,883
Weighted Average Interest Rate	20%	14.56%	14.25%	9.62%

CONVERTIBLE, REDEEMABLE PREFE_2

CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Aug. 31, 2016
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000	10,000,000
Preferred Stock, Dividend Rate, Percentage	4%
Preferred Stock, Liquidation Preference Per Share	$ 1
Preferred Stock, Redemption Terms	The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”).
Preferred Units, Description	In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for the purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period	11,370,178
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	$ 123,582	$ 65,880

TREASURY STOCK SHARES (Details)

TREASURY STOCK SHARES (Details) - shares	Jan. 22, 2024	Jun. 30, 2024
TREASURY STOCK SHARES (Details) [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture	52,100,000
Treasury Stock, Common, Shares		52,100,000
Top Professional Management Group Inc [Member]
TREASURY STOCK SHARES (Details) [Line Items]
Subsidiary, Ownership Percentage, Parent	51%

SHAREHOLDERS' DEFICIT (Details)

SHAREHOLDERS' DEFICIT (Details)	Jan. 22, 2024 USD ($) $ / shares shares	Jan. 16, 2024 $ / shares shares	Jan. 02, 2024 $ / shares shares	Nov. 24, 2023 $ / shares shares	Nov. 22, 2023 $ / shares shares	Oct. 30, 2023 USD ($) $ / shares shares	Apr. 20, 2022 shares	Mar. 31, 2022 $ / shares shares	May 26, 2021 $ / shares shares	May 11, 2021 USD ($) shares	Apr. 06, 2021 $ / shares shares	Jun. 30, 2020 shares	Jan. 19, 2017 shares	Jun. 30, 2024 shares	Jun. 30, 2023 shares
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Common Stock, Shares, Issued														21,136,888,326	21,107,018,148
Common Stock, Shares, Outstanding														21,136,888,326	21,107,018,148
Stock Issued During Period, Shares, Acquisitions												510,000,000	16,155,746,000
Number of shareholders						3
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture	52,100,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.02	$ 0.01	$ 0.01	$ 0.02	$ 0.01	$ 0.02		$ 0.075
Stock Issued During Period, Shares, New Issues	52,100,000	500,000	1,000,000	1,000,000	8,000,000		500,000	1,300,000
Stock Issued During Period, Shares, Issued for Services	4,881,311					6,488,867
Stock Issued During Period, Value, Issued for Services (in Dollars) | $	$ 97,626					$ 25,956
Stock Issued During Period, Shares, Restricted Stock Award, Gross	1,000,000					7,000,000
Long-Term Debt, Gross (in Dollars) | $	$ 40,000					$ 40,000
Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars) | $	$ 20,000					$ 28,000
Imediplus Inc. [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions											70,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											2,500,000
Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions										31,212,000		510,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											510,000,000	510,000,000
Number of shareholders											2
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture											50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares									$ 0.00001		$ 0.00001
Stock Issued During Period, Shares, New Issues									35,000,000
Sale of Stock, Number of Shares Issued in Transaction										71,163
Additional shares										35,000,000
Imediplus Inc. [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage											5%
Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage											51%	51%		51%
Top Professional Management Group Inc [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage	51%
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares									$ 0.00001
Proceeds from Issuance or Sale of Equity (in Dollars) | $										$ 2,340,000
Stock Issued During Period, Shares, New Issues									35,000,000	35,000,000
Investment Amount (in Dollars) | $										$ 2,340,000
Sale of Stock, Number of Shares Issued in Transaction										68,372
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage										6%
Stock Issued During Period, Shares, New Issues										35,000,000
Investment Amount (in Dollars) | $										$ 2,340,000

EQUITY INVESTMENT (Details)

EQUITY INVESTMENT (Details)	Jan. 22, 2024 $ / shares shares	Jan. 16, 2024 $ / shares shares	Jan. 02, 2024 $ / shares shares	Nov. 24, 2023 $ / shares shares	Nov. 22, 2023 $ / shares shares	Oct. 30, 2023 $ / shares	Apr. 20, 2022 shares	Mar. 31, 2022 $ / shares shares	May 26, 2021 $ / shares shares	May 11, 2021 USD ($) shares	Apr. 06, 2021 $ / shares shares	Jun. 30, 2020 shares	Jan. 19, 2017 shares	Jun. 30, 2024
EQUITY INVESTMENT (Details) [Line Items]
Number of shareholders						3
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture	52,100,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.02	$ 0.01	$ 0.01	$ 0.02	$ 0.01	$ 0.02		$ 0.075
Stock Issued During Period, Shares, New Issues	52,100,000	500,000	1,000,000	1,000,000	8,000,000		500,000	1,300,000
Stock Issued During Period, Shares, Acquisitions												510,000,000	16,155,746,000
Losses Exceeded the Investment Percentage														51%
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											510,000,000	510,000,000
Number of shareholders											2
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture											50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares									$ 0.00001		$ 0.00001
Stock Issued During Period, Shares, New Issues									35,000,000
Sale of Stock, Number of Shares Issued in Transaction										71,163
Stock Issued During Period, Shares, Acquisitions										31,212,000		510,000,000
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage											51%	51%		51%
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares									$ 0.00001
Proceeds from Issuance or Sale of Equity (in Dollars) | $										$ 2,340,000
Stock Issued During Period, Shares, New Issues									35,000,000	35,000,000
Investment Amount (in Dollars) | $										$ 2,340,000
Sale of Stock, Number of Shares Issued in Transaction										68,372
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage										6%
Stock Issued During Period, Shares, New Issues										35,000,000
Investment Amount (in Dollars) | $										$ 2,340,000

EQUITY INVESTMENT - Schedule of

EQUITY INVESTMENT - Schedule of Equity Method Investments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Equity Method Investments [Line Items]
Sales	$ 294,670	$ 204,308
Gross profit	169,750	168,588
Net loss	(1,226,362)	(777,340)
51% share	5,791	15,920
Net assets	323,478	299,129
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
51% ownership	1,030,986	1,231,113
Beginning balance of investment, May 11, 2021	5,450	5,450
Loss on equity investment - accumulated	(5,450)	(5,450)
Ending balance of investment, June 30, 2024		0
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
Sales	61,457	270,931
Gross profit	61,457	246,441
Net loss	(294,904)	(307,359)
51% share	(150,401)	(156,753)
Total assets	3,092,663	3,192,224
Net assets	$ 2,021,541	$ 2,203,484

EQUITY INVESTMENT - Schedule _2

EQUITY INVESTMENT - Schedule of Equity Method Investments (Parentheticals) (Details) - Purecell Group [Member]	Jun. 30, 2024	Apr. 06, 2021	Jun. 30, 2020
Schedule of Equity Method Investments [Line Items]
Share	51%	51%	51%
Ownership	51%	51%	51%

INCOME TAXES (Details)

INCOME TAXES (Details)	12 Months Ended
	Jun. 30, 2024 USD ($)
INCOME TAXES (Details) [Line Items]
Unified Corporate Income Tax Rate	25%
Corporate Income Tax Rate For Qualified High Technology And Science Enterprises	15%
Foreign Tax Jurisdiction [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards (in Dollars)	$ 7,924,234

INCOME TAXES - Schedule of Effe

INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
State tax, net of fed effect-US	7%	7%
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income tax benefit at federal statutory rate	21%	21%
Change in valuation allowance	(28.00%)	(28.00%)
Foreign Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income tax benefit at federal statutory rate	25%	25%
Change in valuation allowance	(25.00%)	(25.00%)

INCOME TAXES - Schedule of Defe

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Deferred Tax Assets And Liabilities Abstract
Net operating loss carryforwards	$ 7,924,234	$ 6,697,872
Less: valuation allowance	(7,924,234)	(6,697,872)
Net deferred tax assets	$ 0	$ 0

LEASE (Details)

LEASE (Details)	12 Months Ended
	Jun. 30, 2024 USD ($)
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 80,438
Minimum [Member] | GKT, Alhambra, LP [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	4,939.17
Minimum [Member] | SoCal Industrial LLC [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 1,940.4

LEASE - Lease, Cost (Details)

LEASE - Lease, Cost (Details)	12 Months Ended
	Jun. 30, 2024 USD ($)
Lease, Cost [Abstract]
Cash paid for operating lease liabilities	$ 80,438
Weighted-average remaining lease term	1 year 11 months 1 day
Weighted-average discount rate	5%
Minimum future lease payments	$ 45,475

LEASE - Lessee, Operating Lease

LEASE - Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Lessee Operating Lease Liability Maturity Abstract
2025	$ 23,355
2026	22,120
Total minimum payments	45,475
Less: imputed interest	(2,215)
Total lease liability	43,260
Less: short-term lease liability	(21,683)	$ (41,918)
Long-term lease liability	$ 21,577	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)				1 Months Ended
	Oct. 30, 2024	Sep. 20, 2024	Aug. 26, 2024	Sep. 15, 2024
SUBSEQUENT EVENTS (Details) [Line Items]
Target sales			$ 1,000,000
Stock Issued During Period, Value, New Issues	$ 9,116			$ 68,000
Stock Issued During Period, Shares, New Issues (in Shares)	1,823,282			5,200,000
Professional Fees		$ 8,000
Incremental Common Shares (in Shares)		6,800,000
Second and Third Year [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Target sales			$ 5,000,000